CLDN17: The Putative Drug Target and Biomarker for Prostate and Lung Cancer

Target Name: CLDN17

NCBI ID: G26285

CLDN17

CLDN17: The Putative Drug Target and Biomarker for Prostate and Lung Cancer

Claudin 17 (CLDN17) is a protein that is expressed in various tissues of the body, including the lungs, prostate, and lymph nodes. It is a member of the claudin family, which includes several other proteins that play important roles in the regulation of cell signaling and the expression of cellular processes. One of the most significant functions of CLDN17 is its role in cancer progression.

Recent studies have identified CLDN17 as a potential drug target for prostate and lung cancer. These studies have shown that inhibiting the activity of CLDN17 can lead to the regression of these types of cancer tumors. Additionally, CLDN17 has also been shown to be a biomarker for these types of cancer, which can be used as a target for personalized medicine.

The Role of CLDN17 in Cancer Progression

CLDN17 is a protein that has been shown to play a role in the regulation of cancer cell growth and survival. It is expressed in various tissues of the body, including the lungs, prostate, and lymph nodes, and has been shown to be involved in the development and progression of prostate and lung cancer.

One of the most significant functions of CLDN17 is its role in cell signaling. CLDN17 is a co-factor for the protein PD-L1, which is a key regulator of immune cell function. PD-L1 has been shown to promote the growth and survival of cancer cells by suppressing the immune response.

In addition to its role in cell signaling, CLDN17 has also been shown to play a role in the regulation of cell death. It is a member of the death domain family of proteins, which includes proteins that are involved in the regulation of cell death. CLDN17 has been shown to promote the programmed cell death (apoptosis) of cancer cells, which is a natural mechanism that helps to remove damaged or dysfunctional cells from the body.

The Potential of CLDN17 as a Drug Target

The identification of CLDN17 as a potential drug target for prostate and lung cancer has significant implications for the development of new treatments for these types of cancer. In order to understand the potential of CLDN17 as a drug target, it is important to consider its underlying biology.

CLDN17 is a protein that is expressed in various tissues of the body, including the lungs, prostate, and lymph nodes. It is a member of the claudin family, which includes several other proteins that play important roles in the regulation of cell signaling and the expression of cellular processes. One of the most significant functions of CLDN17 is its role in cancer progression.

In order to understand the potential of CLDN17 as a drug target, it is important to consider its underlying biology. CLDN17 is a protein that is involved in the regulation of cell signaling and cell death. It is a member of the death domain family of proteins, which includes proteins that are involved in the regulation of cell death. CLDN17 has been shown to promote the programmed cell death (apoptosis) of cancer cells, which is a natural mechanism that helps to remove damaged or dysfunctional cells from the body.

In addition to its role in cell signaling and cell death, CLDN17 has also been shown to play a role in the regulation of cancer cell growth and survival. It is expressed in various tissues of the body, including the lungs, prostate, and lymph nodes, and has been shown to be involved in the development and progression of prostate and lung cancer.

The identification of CLDN17 as a potential drug target for prostate and lung cancer has significant implications for the development of new treatments for these types of cancer. In order to fully understand the potential of CLDN17 as a drug target, it is important to consider its underlying biology and the specific functions of CLDN17

Protein Name: Claudin 17

Functions: Channel-forming tight junction protein with selectivity for anions, including chloride and bicarbonate, and for solutes smaller than 9 Angstrom in diameter. In the kidney proximal tubule, may be involved in quantitative reabsorption of filtered anions. Does not affect water permeability

The "CLDN17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets